Abstract: Disclosed herein are methods for generating dopaminergic neurons in vitro by inhibiting a pathway component of a TGF-? signaling pathway and overexpressing one or more cell fate-inducing polypeptides in pluripotent cells, causing differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease.
Abstract: The invention features methods and kits for treating or inhibiting the development of Parkinson's Disease by administering 7-chloro-4-aminoquinoline compounds, e.g., amodiaquine or glafenine. Stem cells are also useful in the methods of the invention and may be administered separately from or together with 7-chloro-4-aminoquinoline compounds. The invention further features methods of identifying additional chemical compounds that are useful in the treatment or inhibition of the development of Parkinson's Disease.
Type:
Grant
Filed:
February 15, 2007
Date of Patent:
February 14, 2012
Assignee:
The McLean Hospital Corporation
Inventors:
Deog Joong Kim, Chun Hyung Kim, Kwang Soo Kim
Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
Type:
Application
Filed:
September 28, 2011
Publication date:
January 26, 2012
Applicant:
THE MCLEAN HOSPITAL CORPORATION
Inventors:
Michael L. Rohan, Perry Renshaw, Aimee Parow
Abstract: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.
Type:
Application
Filed:
December 14, 2009
Publication date:
January 12, 2012
Applicant:
The McLean Hospital Corporation
Inventors:
Cecile Beguin, Justin Stephen Potuzak, Thomas Anthony Munro, Katherine K. Duncan, William A. Carlezon, Bruce M. Cohen, Lee-yuan Liu Chen
Abstract: Provided are methods for diagnosing the presence, type, or severity of a dementia in a human subject. The methods involve using a computer-based system to assess impairment of certain cognitive and motor functions that are indicative of Alzheimer's disease and other forms of dementia.
Abstract: A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.
Abstract: The invention features derivatives of R(?)-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
Type:
Grant
Filed:
October 12, 2006
Date of Patent:
November 1, 2011
Assignee:
McLean Hospital Corporation
Inventors:
Michael L. Rohan, Perry Renshaw, Aimee Parow
Abstract: The present invention relates to techniques and systems for training a subject to modify his or her own neutronal activity within a selected brain region.
Type:
Application
Filed:
November 4, 2009
Publication date:
October 27, 2011
Applicant:
MCLEAN HOSPITAL CORPORATION
Inventors:
Elizabeth Quattrocki-Knight, Bruce Cohen
Abstract: The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
Abstract: The invention features methods and systems to provide, in one test session, information on the patient's sensitivity to a probe drug for treating attentional disorders. The methods and systems of the invention can enable clinicians and consumers to ascertain how much benefit an individual would derive from treatment, what dose would be required, and the acute effect of that dose on regularity and rhythmicity of their heartbeat.
Abstract: The invention features methods and systems to monitor changes in the magnitude of attentional disturbance and the magnitude of motor activity disturbance in a subject. The invention also features methods and systems for determining a subject's degree of concordance with individuals having an attentional disorder versus individuals not having an attentional disorder. The methods and systems of the invention can enable clinicians and consumers to ascertain both the severity of an attentional disorder as well as how much an individual changes over time, or with therapy.
Abstract: The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, uridine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
Abstract: The invention provides methods for determining shifts in the attentional state of a subject. These methods are useful for diagnosing subjects with a psychological or behavioral disorder. The invention also features methods for determining the effect of a therapy on the overall attentional state and shifts in the attentional state of a subject.
Abstract: A method for screening a test composition for potential efficacy in treatment of a disorder includes a first computer model representative of a volume of disease-afflicted neural tissue comprising biologically realistic neurons exposed to the test composition; and providing an initial excitation to the first computer model. Following a selected computation interval, a first outcome is determined. The first outcome indicates a response of the first computer model to the initial excitation and indicates whether the test composition has the potential to be effective in treating the disorder.
Abstract: The invention features derivatives of R(?)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
Abstract: The invention features methods of treating mood disorders, such as manic disorders, and stabilizing moods by administering a kappa agonist or partial agonist to a subject in need thereof.
Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.
Type:
Application
Filed:
May 2, 2008
Publication date:
January 13, 2011
Applicant:
The McLean Hospital Corporation
Inventors:
Anne M. Cataldo, Peter A. Paskevich, Bruce M. Cohen
Abstract: The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.